Clinical Trials
388 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
Clinical Genetics Branch Eligibility Screening Survey
National Institutes of Health Clinical Center (CC)
MK-3475-G21
Merck Sharp & Dohme LLC
M7824 Related Adverse Effects in Adults With Cancer
National Institutes of Health Clinical Center (CC)
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
FOCUS
Ohio State University Comprehensive Cancer Center
SURVIMON
N.N. Petrov National Medical Research Center of Oncology
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
OP-NEU-101
Onchilles Pharma Inc
ACTengine
Immatics US, Inc.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
PanRAF
Royal Marsden NHS Foundation Trust
LONGEVITI
University of Alberta
IRIS
University of Pittsburgh
A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
University of Florida
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Project: Every Child for Younger Patients With Cancer
Children's Oncology Group
Evaluation for NCI Surgery Branch Clinical Research Protocols
National Institutes of Health Clinical Center (CC)
Harvesting Cells for Experimental Cancer Treatments
National Institutes of Health Clinical Center (CC)
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
ELEPHAS-02
Elephas
SESAME
Northwestern University
NAVIGATE
Bayer
CER
Cancer Support Community, Research and Training Institute, Philadelphia
ARTACUS
Replimune, Inc.
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
COMBI-AD
Novartis
NST-628
Nested Therapeutics, Inc
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
RELI
Maastricht University Medical Center
TirbAKare
Almirall, S.A.
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
The Christie NHS Foundation Trust
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
MK-4700-001
Merck Sharp & Dohme LLC
PALANGI3
Centre Oscar Lambret
Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma
Mayo Clinic
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
COLUMBUS
Pfizer
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers
AI Labs Group S.L
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
The Florida ASCENT Study
University of Florida
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc